RxDoctor Payments Data

Anil Singh, MD

Cardiology · Cumberland, MDNPI 1770587313

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $427 and has fallen 57.4% since, to $182 in 2025.

$2,026in general payments, 2019–2025

Across 102 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$459
  • Merck$200
  • Actelion Pharmaceuticals US, Inc.$175
  • Johnson & Johnson$171
  • Boehringer Ingelheim$170
  • Pfizer$160
  • plus $692 from 15 others

What the payments were for

  • Food & beverage$1,92495%
  • Education$1025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,026 in reported general payments places this provider in the 80th percentile of 44 cardiology providers in Maryland.

See all cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$1,410,450
Medicare patients
2,975
Services billed
11,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban97$86,591
EliquisApixaban98$77,673
EntrestoSacubitril/Valsartan16$13,355
Metoprolol Succinate146$2,430
Ezetimibe37$1,513
Atorvastatin Calcium128$1,129
Terazosin Hcl26$1,016
Flecainide Acetate17$1,001
Lisinopril118$972
Amlodipine Besylate154$926
Isosorbide Mononitrate ErIsosorbide Mononitrate103$852
Metoprolol Tartrate167$828
Losartan Potassium88$808
Ramipril31$646
Potassium Chloride34$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$171$86,59197 claims
PfizerEliquis$160$77,67398 claims
NovartisEntresto$53$13,35516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 44 cardiology providers in Maryland.

Other cardiology in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →